<DOC>
	<DOCNO>NCT00821964</DOCNO>
	<brief_summary>This phase II trial study side effect give topical imiquimod together Abraxane ( paclitaxel albumin-stabilized nanoparticle formulation ) see well work treat patient advance breast cancer . Biological therapy , imiquimod , may stimulate immune system kill tumor cell . Drugs use chemotherapy , Abraxane , work different way stop growth tumor cell , either kill cell stop divide . Giving imiquimod together Abraxane may kill tumor cell .</brief_summary>
	<brief_title>Topical Imiquimod Abraxane Treating Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety chemoimmunotherapy topical imiquimod Abraxane breast cancer patient recurrent chest wall disease cutaneous metastasis . II . To evaluate anti-tumor effect chemoimmunotherapy topical imiquimod Abraxane breast cancer patient recurrent chest wall disease cutaneous metastasis . SECONDARY OBJECTIVES : I . To examine whether treatment chemoimmunotherapy consist topical imiquimod Abraxane augments endogenous tumor specific immunity . II . To assess effect chemoimmunotherapy circulate transform growth factor ( TGF ) -beta level . OUTLINE : Patients receive Abraxane intravenously ( IV ) 30 minute day 1 , 8 , 15 apply topical imiquimod cutaneous lesion daily ( QD ) day 1-4 , 8-11 , 15-18 , 22-25 . Treatment repeat every 28 day 3 cycle absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 , 4 , 8 , 12 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients advance stage refractory breast cancer Progressive relapse disease follow standard therapy chemotherapy and/or surgery , and/or radiation Patients must measurable ( bidimensional ) chest wall disease and/or cutaneous metastatic lesion Patients must least 7 day last chemotherapy 30 day local radiotherapy and/or systemic steroid Patients bisphosphonates , trastuzumab , lapatinib and/or hormonal therapy eligible White blood cell count &gt; = 1000/ul Absolute neutrophil count ( ANC ) &gt; = 1200/ul Platelets &gt; 75,000/ul Serum creatinine = &lt; 2.0 mg/dL , creatinine clearance &gt; 60 ml/min Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2 X upper limit normal ( ULN ) Total bilirubin &lt; 2 X ULN Patients must Performance Status Score ( Eastern Cooperative Oncology Group [ ECOG ] Scale ) = &lt; 2 Patients must recover major infection and/or surgical procedure , opinion investigator , significant active concurrent medical illness preclude protocol treatment Men woman reproductive ability must agree contraceptive use study 1 month imiquimod/Abraxane treatment discontinue Patients prior allergic reaction taxanes Patients clinically significant active autoimmune disease require active treatment systemic steroid immunomodulators Pregnant breastfeed woman Patients peripheral neuropathy &gt; = Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Stage IV</keyword>
	<keyword>cream</keyword>
	<keyword>topical</keyword>
</DOC>